As covered in Biospace, SignalPath, a healthcare technology company developing innovative software tools that dramatically improve the ease and efficiency of trial execution and management, today announced the formation of the SignalPath Research Consortium. By partnering with technology companies, life sciences sponsors, and cutting edge research sites, SignalPath is building an ecosystem to empower the redesign of clinical trials.
Greg Simon, Biden Cancer Initiative President, said, “We are thrilled for SignalPath to announce this important initiative at our Summit and align with their efforts to leverage technology, starting at the point of care in clinics, to enable innovative therapies to reach cancer patients more quickly and economically.”
The SignalPath Research Consortium is a rapidly growing network of sophisticated clinical trials sites connected via a technical foundation. New York Cancer and Blood Specialists is a leading example; this innovative community-based oncology practice is deploying SignalPath’s novel operational, financial, oversight and study start-up software to support the conduct of research at their sites. “By converting clinical trial protocols into a digital footprint that runs behind the scenes, SignalPath has developed workflow tools for sites that are simple, intuitive, and easy to use. I expect this will dramatically improve our ability to deliver on our research mission to bring life-saving therapies to cancer patients more quickly,” said Jeff Vacirca, M.D., CEO, New York Cancer and Blood Specialists.